Associated Papers
Association of mutation profiles with metastasis in patients with non-small cell lung cancer.
Li Y et al.
Frontiers in Oncology, 2024
39464712 (PubMed )
Supplement: Table3.xlsx › LMG____
Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant.
Soon Jian Hao J et al.
Cold Spring Harbor Molecular Case Studies, 2022
36577523 (PubMed )
Supplement: supp_mcs.a006223_Supplemental_Material.pdf
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing.
Lee J et al.
Journal of Pathology and Translational Medicine, 2022
Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung.
Wang H et al.
Frontiers in Oncology, 2022
EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes.
Xu H et al.
Frontiers in Oncology, 2021
A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients.
Zhang X et al.
World Journal of Surgical Oncology, 2020
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Mack PC et al.
Cancer, 2020
Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.
Dono M et al.
Molecular Medicine (cambridge, Mass.), 2019
Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.
Ghafoor Q et al.
Pathology Oncology Research : Por, 2018
Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm.
De Luca C et al.
Journal of Clinical Pathology, 2018
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.
Kobayashi Y et al.
Cancer Science, 2016
Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Zhang Q et al.
Cancer Chemotherapy and Pharmacology, 2016
Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.
Zhou J et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2016
[Molecular profiling of non-small cell lung cancer].
Gibault L et al.
Revue De Pneumologie Clinique, 0
Select a paper to view details